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ttps://doi.org/10.1016/j.jmoldx.2018.05.005BRCA1/2 variant analysis in tumor tissue could streamline the referral of patients with epithelial
ovarian, fallopian tube, or primary peritoneal cancer to genetic counselors and select patients who
beneﬁt most from targeted treatment. We investigated the sensitivity of BRCA1/2 variant analysis in
formalin-ﬁxed, parafﬁn-embedded tumor tissue using a combination of next-generation sequencing and
copy number variant multiplex ligation-dependent probe ampliﬁcation. After optimization using a
training cohort of known BRCA1/2 mutation carriers, validation was performed in a prospective cohort
in which screening of BRCA1/2 tumor DNA and leukocyte germline DNA was performed in parallel. BRCA1
promoter hypermethylation and pedigree analysis were also performed. In the training cohort, 45 of 46
germline BRCA1/2 variants were detected (sensitivity, 98%). In the prospective cohort (nZ 62), all six
germline variants were identiﬁed (sensitivity, 100%), together with ﬁve somatic BRCA1/2 variants and
eight cases with BRCA1 promoter hypermethylation. In four BRCA1/2 variantenegative patients, sur-
veillance or prophylactic management options were offered on the basis of positive family histories. We
conclude that BRCA1/2 formalin-ﬁxed, parafﬁn-embedded tumor tissue analysis reliably detects BRCA1/
2 variants. When taking family history of BRCA1/2 variantenegative patients into account, tumor
BRCA1/2 variant screening allows more efﬁcient selection of epithelial ovarian cancer patients for
genetic counseling and simultaneously selects patients who beneﬁt most from targeted treatment.
(J Mol Diagn 2018, 20: 600e611; https://doi.org/10.1016/j.jmoldx.2018.05.005)Supported by AstraZeneca (ﬁnancial support for next-generation
sequencing).
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Disclosures: None declaredGermline BRCA1/2 pathogenic variants confer elevated life-
time risks for epithelial ovarian cancer (EOC), and especially
for high-grade serous ovarian, fallopian tube, and primary
peritoneal cancers (HGSCs).1e3 Analysis of 489 HGSCs by
The Cancer Genome Atlas Research Network demonstrated
that germline BRCA1/2 variants, somatic BRCA1/2 variants,
and epigenetic silencing of BRCA1 via promoter hyper-
methylation are frequent events, found in approximately
16%, 7%, and 11% of cases, respectively.4 Other studies
reported comparable rates of BRCA1/2 defects.1,3,5e8
The high prevalence of pathogenic germline BRCA1/2
variants in EOC patients led to the generally accepted
recommendation that all women diagnosed with EOCstigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgshould receive genetic counseling and be offered genetic
testing, with some slight differences observed between
countries.9,10 In the Netherlands, BRCA1/2 variant screening
is recommended for every EOC patient, irrespective of
family history, age, and histologic subtype.10
BRCA1 and BRCA2 have multiple roles in maintaining
genome integrity and are crucial for high-ﬁdelity repair
of DNA double-strand breaks via homologousolecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
BRCA1/2 Screening in Tumor Tissuerecombinationemediated repair.11,12 BRCA1/2-deﬁcient tu-
mors show speciﬁc genomic aberrations associated with this
homologous recombination repair deﬁciency.13e15 The
platinum sensitivity frequently observed in HGSC is
thought to be related to the underlying homologous
recombination repair deﬁciency, because homologous
recombination repair is involved in the repair of DNA
damage induced by these agents.13,16,17 Another group of
drugs that exploit the presence of homologous recombina-
tion repair deﬁciency in tumor cells are the poly (ADP-
ribose) polymerase (PARP) inhibitors. By increasing the
burden on homologous recombination repair, these drugs
induce synthetic lethality in tumor cells with acquired ho-
mologous recombination repair deﬁciency.11,18
Multiple studies have shown that PARP inhibitors
improve progression-free survival (PFS) in platinum-
sensitive recurrent EOC.19e23 Although recent studies also
reported a signiﬁcantly longer PFS of patients with relapsed
platinum-sensitive BRCA1/2 wild-type HGSC receiving
niraparib20 or olaparib19 compared with placebo treatment,
most of the PFS beneﬁt was observed for patients with
pathogenic BRCA1/2 variants. Therefore, identiﬁcation of
patients with either a somatic or a germline BRCA1/2 variant
would signiﬁcantly improve the selection of patients who
beneﬁt most from PARP inhibition.19,20,23
Although pathogenic germline BRCA1/2 variants are
relatively common in EOC patients, most (approximately
85%) do not have a BRCA1/2 variant. Referring all women
with EOC for genetic counseling is, therefore, inefﬁcient
and causes unnecessary distress. This problem could be
overcome by the integration of a reliable tumor screening
test in the care pathway of ovarian cancer patients. A test for
genetic variants in BRCA1/2 should be capable of detecting
both germline and somatic variants using tumor DNA
derived from formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue. Initial use of a tumor DNA test, followed by referral
of only those patients with a BRCA1/2 variant (somatic or
germline) for genetic counseling, would avoid an estimated
80% of referrals.
The analysis of BRCA1/2 in low-quality, highly frag-
mented FFPE-derived tumor DNA is technically challenging
because BRCA1/2 are both large genes with a wide mutation
spectrum.24e28 Several studies, mainly using high-quality
blood-derived DNA, have shown that next-generation
sequencing (NGS) can reliably detect BRCA1/2 var-
iants.25,29e31 Studies analyzing the performance of NGS in
FFPE-derived DNA have shown promising results,25,32e34
but none of the studies simultaneously analyzed high-
quality blood-derived DNA in a prospective setting.
The aim of this study was to investigate the performance
of BRCA1/2 variant analysis in DNA isolated from FFPE
tumor tissue in comparison with sequencing of leukocyte
DNA (currently the gold standard in BRCA1/2 variant
screening). On the basis of the results, we recommend
integrating tumor screening within the care pathway of
ovarian cancer patients.The Journal of Molecular Diagnostics - jmd.amjpathol.orgMaterials and Methods
Tissue Sample and Patient Selection
Training Cohort
The 50 patients in the retrospective training cohort were
collected as follows. First, 67 patients were randomly
selected who fulﬁlled the following selection criteria: pre-
viously identiﬁed germline BRCA1/2 pathogenic variants at
the Laboratory for Diagnostic Genome Analysis of the
Leiden University Medical Center and breast or gynecologic
malignancy. From this cohort, 33 samples were selected by
expert clinical molecular geneticists (J.T.W. and N.v.d.S.)
for pathogenic variants that were potentially challenging to
detect, including deletions, insertions, and variants in
ﬂanking introns and homopolymer regions. An additional
17 cases with pathogenic germline variants were randomly
selected (not based on type of variant) to reach a total of 50
cases (Figure 1A).
COBRA Cohort
For the prospective clinical implementation of BRCA1/2
screening on ovarian tumor tissue (COBRA) cohort, women
were recruited in seven participating hospitals in the
southwestern region of the Netherlands from February 2016
to June 2017. Women with (a history of) EOC and not
previously screened for germline BRCA1/2 variants were
eligible for inclusion. The cohort was enriched for HGSCs.
After inclusion, leukocyte DNA was used for routine
germline analysis at the Department of Clinical Genetics.
Simultaneously, FFPE tumor tissue blocks were collected
for parallel tumor BRCA1/2 screening at the Department of
Pathology, thus allowing detection of both somatic and
germline variants (Figure 1B). The study was approved by
the medical ethics committee of the Leiden University
Medical Center (reference number P16.009). Sixty-six
women gave signed informed consent and were included.
Routine germline BRCA1/2 screening and tumor BRCA1/2
screening were requested simultaneously, either directly by
the treating physician (gynecologist or medical oncologist)
or by the clinical geneticist.
Histopathology slides from all cases were revised by an
expert gynecopathologist (T.B.) in line with the most recent
(2014) World Health Organization classiﬁcation system.Family History
Pedigrees including ﬁrst-, second-, and third-degree rela-
tives were constructed on the basis of questionnaires. The
pedigrees were evaluated by expert clinical geneticists
(C.J.v.A., M.N.) for tumor types and age of onset. All
family histories of BRCA1/2-negative cases were classi-
ﬁed on the basis of the presence or absence of an
indication for extra surveillance or management options
for ﬁrst-degree relatives, according to current national
guidelines.601
Figure 1 Schematic overview of cohort selec-
tion. A: Training cohort. Copy number variant-
multiplex ligation-dependent probe ampliﬁcation
(CNV-MLPA) was performed only for cases in which
no variant was automatically identiﬁed via the Ion
Torrent speciﬁc caller, Torrent Variant Caller
version 5.0.2 (Thermo Fisher Scientiﬁc). B: Clinical
implementation of BRCA1/2 screening on ovarian
tumor tissue cohort. Of the 33 cases selected for
variants that were potentially more challenging to
detect in the training cohort, two had insufﬁcient
tumor tissue for analysis. MS, methylation speciﬁc;
NGS, next-generation sequencing.
de Jonge et alDNA Isolation
Tumor DNA was isolated from FFPE blocks from routine
diagnostics. In most cases, the tumor tissue underwent at
least overnight ﬁxation in formalin. For isolation, either
three 0.6-mm tissue cores or the microdissected tumor areas
from ﬁve 10-mm tissue sections were used. For the purposes
of optimization, DNA from paired normal FFPE tissue was
isolated and analyzed for a subset of cases in both the
training cohort and the COBRA cohort. The mean tumor
percentage was 61% (range, 30% to 90%) for the training
cohort and 65% (range, 10% to 95%) for the COBRA
cohort. For NGS and methylation-speciﬁc multiplex
ligation-dependent probe ampliﬁcation (MLPA), DNA was
isolated using the automated Tissue Preparation System
(Siemens Healthcare Diagnostics, Erlangen, Germany), as
described previously.35 For copy number variant (CNV)
MLPA, crude DNA was manually isolated using overnight
proteinase K digestion. FFPE tissue cores did not undergo
deparafﬁnization. For microdissected samples, deparafﬁni-
zation in xylene was performed, followed by rehydration
through a graded ethanol series and staining with hema-
toxylin. Also, 20 mL of 20% chelex was added during
overnight proteinase K digestion. After overnight incubation
in a heat block at 56C, samples were heated for 10 minutes
at 99C and centrifuged at 13,000  g at 4C, after which
the chelex was removed from the microdissected samples.
DNA was quantiﬁed using the Qubit dsDNA HS Assay Kit,
according to manufacturer’s instructions (Qubit 2.0 Fluo-
rometer; Life Technologies, Carlsbad, CA).602Next-Generation Sequencing
BRCA1 and BRCA2 AmpliSeq NGS libraries were prepared
using the Oncomine BRCA Research panel (Thermo Fisher
Scientiﬁc, Waltham, MA), according to the manufacturer’s
protocol. The panel contains 265 amplicons and covers
100% of the coding sequences of BRCA1 and BRCA2, and it
also includes ﬂanking intronic sequences (average, 64 bases
in 50 and 30 direction). Insert sizes (ie, the amplicon minus
the primers) range from 65 to 138 bp. NGS libraries were
equimolary pooled to 60 pmol/L, and the ﬁnal library pool
was loaded on an Ion PI Chip (Thermo Fisher Scientiﬁc)
using an Ion Chef instrument (Thermo Fisher Scientiﬁc).
Sequencing was performed in an Ion Proton system
(Thermo Fisher Scientiﬁc).
Multiplex Ligation-Dependent Probe Ampliﬁcation
CNV-MLPA was performed using the SALSA MLPA
probe mix P002 BRCA1 (MRC-Holland, Amsterdam, the
Netherlands) on approximately 37.5 ng of DNA in a 20-mL
reaction, according to manufacturer’s protocol, with small
adaptations. Brieﬂy, the SALSA probe mix and MLPA
buffer were added to a solution containing approximately
37.5 ng of DNA, and the mix was denatured for 10 minutes
at 95C, followed by hybridization at 60C for 16 to 20
hours. Next, for ligation, the Master mix (ligase buffer A,
ligase buffer B, and Ligase-65 enzyme) was added at 54C
and samples were heated for 20 minutes at 54C, followed
by 5 minutes at 98C. The PCR master mix (includingjmd.amjpathol.org - The Journal of Molecular Diagnostics
BRCA1/2 Screening in Tumor TissueSALSA primer mix and SALSA polymerase) was then
added, and the following PCR was performed for 35 cycles:
30 seconds at 95C, 30 seconds at 60C, and 60 seconds at
72C, followed by incubation for 20 minutes at 72C. For
the training cohort, CNV-MLPA was only performed for
cases in which no variant was identiﬁed via NGS data
analysis. In the COBRA cohort, CNV-MLPA was per-
formed in all cases for which sufﬁcient tumor tissue was
available.
Methylation-speciﬁc MLPA using the SALSA MLPA
ME001 tumor suppressor mix (MRC-Holland) was per-
formed, according to the manufacturer’s protocol, with
some adaptations. After denaturation of approximately 75
ng of DNA for 5 minutes at 98C, the SALSA probe mix
and MLPA buffer were added and samples were incubated
for 1 minute at 98C, followed by hybridization at 60C for
16 to 20 hours. Then, ligase buffer A was added at room
temperature, and the samples were heated for 2 minutes at
48C. Samples were then split and ligated for 30 minutes at
48C (ligase buffer B and Ligase-65 enzyme, with or
without the addition of HhaI enzyme), followed by heating
for 5 minutes at 98C. After the master mix was added
(SALSA primer mix and SALSA polymerase), a PCR was
performed for 35 cycles (30 seconds at 95C, 30 seconds at
60C, and 60 seconds at 72C), followed by incubation for
20 minutes at 72C. Methylation-speciﬁc MLPA was per-
formed for all cases from the COBRA cohort with a [DNA]
>7 ng/mL. MLPA data were analyzed using Coffalyser.Net
software version 140721.1958 (MRC-Holland).
For both tests, the ABI 3130 genetic analyzer (Applied
Biosystems, Foster City, CA) was used for separation of the
products by electrophoresis.
Data Analysis
The unaligned bam ﬁles generated by the proton sequencer
were mapped against the human reference genome (GRCh37/
hg19) using the TMAP 5.0.7 softwarewith default parameters
(https://github.com/iontorrent/TS, last accessed March 6,
2018). Subsequent variant calling was done using the Ion
Torrent speciﬁc caller, Torrent Variant Caller 5.0.2 (Thermo
Fisher Scientiﬁc), using the recommended somatic variant
caller parameter for the BRCA Oncomine Panel. Brieﬂy,
variants were called with a minimum allele frequency
threshold of 3.5% and a read depth of at least 100. Strand
bias and proximity to a homopolymer region were also used
to minimize false positives.
Integrative GenomicsViewerwas used for visual inspection
of the detected variants,36 imported into a local Genetic As-
sistant database (Geneticist Assistant version 1.4.5; SoftGe-
netics, State College, PA),which assigns functional prediction,
conservation scores, and disease-associated information to
each variant. This information is then used to assign patho-
genicity to a variant, and the next time the variant is observed,
the same pathogenicity is automatically attributed to the
observed variant. Variant annotation was based on theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgNM_007294.3 and the NM_000059.3 transcripts to BRCA1
and BRCA2, respectively.28
Data Interpretation
Variants were categorized by ﬁve-tier pathogenicity status
[class 1, benign; class 2, likely benign; class 3, variant of
unknown signiﬁcance (VUS); class 4, likely pathogenic;
and class 5, pathogenic].37
For the training cohort, FFPE-isolated DNA was analyzed
at the pathology department (Leiden University Medical
Center, Leiden, the Netherlands). Although all cases were
known to carry a class 4 or 5 BRCA1 or BRCA2 variant, it
was not known which germline variant was present in the
samples at the time of analysis. All variants identiﬁed were
later compared with the previously identiﬁed germline
variant (Figure 1A). For the COBRA cohort, the BRCA1/2
tumor screening (at the Pathology Department of the Leiden
University Medical Center) was performed concurrently
with, but independently of, routine leukocyte germline
screening (at the Department of Clinical Genetics, Leiden
University Medical Center). On completion, the class 3, 4,
and 5 variants identiﬁed in tumor DNA were compared with
the results of the germline analysis (Figure 1B).
Loss of heterozygosity (LOH) ofBRCA1/2was determined
by comparing the variant allele frequency (VAF)
of heterozygous SNPs and, when present, the VAF of
the BRCA1/2 variant in tumor and normal tissue. LOH
was considered present when the tumor cell percentage was
>20%, the germline BRCA1/2 variant allele frequency was
>60%, and/or at least two informative (heterozygous) single-
nucleotide variants (SNVs) showed a VAF 0.4 or 0.6.
LOH was considered inconclusive when the tumor cell per-
centage was <20% or when only one informative SNV was
present. LOH was considered absent when the germline
BRCA1/2 variant VAF was 0.6 and/or at least two infor-
mative (heterozygous) SNVs showed a VAF between 0.4 and
0.6, unless a clear difference in VAF of the SNV and/or
variant could be observed between the normal DNA sample
and the tumor DNA sample. LOH results were manually
curated (T.v.W./R.v.E.), taking the tumor cell percentage and
the VAF of the SNV or variant into account. SNVs were an-
notated in an in-house database (geneticist assistant).
Quality Control
Sample quality was evaluated by an experienced molecular
biologist (T.v.W. or R.v.E.). Samples with a low coverage, a
high number of low-frequency variants, or a high proportion
of C:G>T:A transitions (ie, artifacts caused by formalin
ﬁxation)26,38 were excluded from further analysis. However,
an unequivocal class 3, 4, or 5 variant identiﬁed in a poor-
quality sample was considered sufﬁcient for analysis. For
the training cohort, a patient was only excluded from the
ﬁnal analysis if both the tumor DNA sample and the normal
DNA sample failed the quality control.603
Table 1 Germline Variants in the Training Cohort
ID Gene c.DNA change*
Amino acid
changey T% VAF tumor VAF normal LOH Histology
R31z BRCA1 c.68dupA p.Cys24fs 40 0.83 0.48 Yes EEC
R12 BRCA1 c.34C>T p.Gln12* 70 0.96 0.43 Yes HGSC
R35z BRCA1 c.81-6T>A p.? 80 0.92 0.53 Yes HGSC
R49 BRCA1 c.181T>G p.Cys61Gly 70 0.81 NA Yes EEC
R11 BRCA1 c.181T>G p.Cys61Gly 70 0.89 0.51 Yes HGSC
R19 BRCA1 c.213-12A>G p.? 40 0.70 0.51 Yes EEC
R28z BRCA1 c.213-12A>G p.? 65 0.74 0.56 Yes Breast-NST
R20 BRCA1 c.(594-2A>C;c.641A>G)x p.? 35 0.57 and 0.61 0.46 and 0.47 NA LGSC
R3z BRCA1 c.1292dupT p.Leu431fs 70 0.77 NA Yes HGSC
R39z BRCA1 c.2019delA p.Glu673fs 60 0.73 0.45 Yes Breast-metaplastic
R34z BRCA1 c.2197_2201delGAGAA p.Glu733fs 60 NA{ 0.51 NA Breast-NST
R2z BRCA1 c.3436_3439delTGTT p.Cys1146fs 55 0.73 0.55 Yes Breast-ILC
R32z BRCA1 c.3481_3491delGAAGATACTAG p.Glu1161fs 80 0.70k NA Yes HGSC
R25z BRCA1 c.3485delA p.Asp1162fs 40 0.61 0.47 Yes HGSC
R47z BRCA1 c.3820dupG p.Val1274fs 80 0.97 0.47 Yes Breast-NST
R44z BRCA1 c.4035delA p.Glu1346fs 40 0.58 0.48 Not
detected
HGSC
R7 BRCA1 c.4327C>T p.Arg1443* 80 0.94 0.48 Yes USC
R14 BRCA1 c.4327C>T p.Arg1443 50 0.73 0.52 Yes HGSC
R17 BRCA1 c.4327C>T p.Arg1443 70 0.84 0.46 Yes HGSC
R4z BRCA1 c.4483delA p.Arg1495fs 60 0.53 0.51 Not
detected
Breast-NST
R9 BRCA1 c.5177_5180delGAAA p.Arg1726fs 90 NAk 0.48 Yes** HGSC
R27z BRCA1 c.5177_5180delGAAA p.Arg1726fs 70 0.92 0.54 Yes Ovarian-mixedyy
R18 BRCA1 c.5266dupC p.Gln1756fs 75 0.99 0.49 Yes EOC
R37z BRCA1 c.5266dupC p.Gln1756fs 50 0.80 0.50 Yes Breast-NST
R5z BRCA2 c.658_659delGT p.Val220fs 60 0.47 0.43 Not
detected
Breast-NST
R48 BRCA2 c.771_775delTCAAA p.Asn257fs 80 0.81 0.56 Yes Breast-NST
R43z BRCA2 c.1147delA p.Ile383fs 50 0.84 NA Yes Breast-NST
R46z BRCA2 c.1147delA p.Ile383fs 60 0.71 0.52 Yes HGSC
R38z BRCA2 c.1899_1900insTT p.Ala634fs 60 0.60 0.49 Yes Breast-mixedzz
R22z BRCA2 c.3599_3600delGT p.Cys1200* 30 0.63 0.41 NA Breast-NST
R24z BRCA2 c.4284dupT p.Gln1429fs 70 xx xx Yes Breast-NST
R33z BRCA2 c.5213_5216delCTTA p.Thr1738fs 80 0.90 NA{ Yes OCS
R10 BRCA2 c.5286T>A p.Tyr1762* 80 0.71 0.62 Yes HGSC
R8 BRCA2 c.5682C>G p.Tyr1894* 60 0.91 0.56 Yes HGSC
R29z BRCA2 c.5946delT p.Ser1982fs 60 0.86 0.52 Yes Breast-NST
R21z BRCA2 c.6270_6271delTA p.His2090fs 40 0.75 0.51 Yes OSC{{
R45z BRCA2 c.6275_6276delTT p.Leu2092fs 70 0.79 0.51 Yes Breast-NST
R42z BRCA2 c.6361_6362delGA p.Glu2121fs 55 0.88 0.47 Yes HGSC
R23z BRCA2 c.6816_6817delAA p.Gly2274fs 70 NA{ 0.38 NA HGSC
R1z BRCA2 c.9099_9100delTCkk p.Gln3034fs 50 0.69 0.30 Yes Breast-NST
R36z BRCA2 c.9295_9301delAATTTAC p.Asn3099fs 60 0.69k*** 0.48k*** Yes HGSC
CNV-MLPA
R50 BRCA1 Deletion of exons 8 and 9 p.? 85 NA{ NAP NA OCS
R15 BRCA1 Deletion of exon 22 p.? 60 NAP NAP NA HGSC
R40z BRCA1 Deletion of exon 22 p.? 30 NAP NA Yes HGSC
R26z BRCA1 c.5503_5564del p.Arg1835fs 30 NAP NAP Yes Breast-NST
R41z BRCA1 c.5503_5564del p.Arg1835fs 35 NAP NAP Yes Breast-NST
*Reference sequences: NM_007294.3 for BRCA1 and NM_000059.3 for BRCA2.
yNP_009225.1 for BRCA1 and NP_000059.3 for BRCA2.
zSelected by expert clinical molecular geneticists for variants potentially more challenging to detect, including deletions, insertions, and variants in ﬂanking
introns and in homopolymer regions.
xReclassiﬁed as a variant of uncertain signiﬁcance.
{Quality control failed.
kAutomatically identiﬁed after adjustment of the alignment settings.
de Jonge et al
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IBM SPSS software version 23.0 (IBM Corp., Armonk,
NY) was used for statistical analysis. A one-way analysis of
variance test was used to compare age distributions, and the
U-test was used for comparison of the age of the tissue
blocks. The association between histotype and BRCA1/2
defects was tested using a two-sided Fisher’s exact test. P 
0.05 was considered signiﬁcant.Results
Training Cohort
Of the 50 cases in the training cohort, three were excluded
because no tumor tissue was available in the archives. For the
remaining 47 patients, matching normal tissue DNA was
analyzed in 42 cases. Forty-six patients could be included in
the ﬁnal analysis because either the tumor (42/47) or the
paired normal (40/42) tissue sample was sequenced with
sufﬁcient quality (Figure 1A); hence, mutation status was
determined on normal FFPE tissue only for four cases. One
case was excluded from the analysis because sequencing re-
sults for both the tumor and the normal DNA were of insuf-
ﬁcient quality. Tissue blocks used for DNA isolation were
signiﬁcantly older for the samples that failed the quality
control (nZ 7; median, 2003; range, 1994 to 2014) compared
with the samples that passed quality control (nZ 82; median,
2008; range, 1986 to 2015; P < 0.05). The median coverage
per amplicon of the samples included in the ﬁnal analysis is
visualized in Supplemental Figure S1. All 265 amplicons had
a median coverage of at least 100 reads. Per sample, 98% of
the amplicons (range, 51.3% to 100%) were covered with a
sequencing depth of at least 100 reads. Sample R27 (normal
FFPE DNA) was an outlier, with only 51.3% of amplicons
covered by >100 reads and 10 amplicons that completely
failed. Nevertheless, a BRCA1 variant was clearly detected,
and the sample was, therefore, considered to be of sufﬁcient
quality for analysis (Supplemental Table S1).
Variant Analysis
The germline variants found in the 46 cases included in the
ﬁnal analysis are listed in Table 1. In 38 of the 46 cases
(83%), a variant (SNV, small insertion, or deletion) was
detected during initial analysis. The BRCA1/2 variants could**Ampliﬁcation of one of the primer pools failed; LOH based on single-nucleot
yyClear cell carcinomaeendometrioid carcinoma.
zzNST-mucinous.
xxNot detected; duplication in homopolymeric region.
{{Grading not reliable because of previous treatment.
kkBecause of noise at the border of an 8-bp adenine stretch, the deletion was
***Detected with prior knowledge of the position of the deletion.
CNV-MLPA, copy number variantemultiplex ligation-dependent probe ampliﬁca
carcinoma; HGSC, high-grade ovarian, fallopian tube, and primary peritoneal cance
carcinoma; LOH, loss of heterozygosity; NA, not analyzed/not analyzable; NAP,
carcinosarcoma; OSC, ovarian serous carcinoma; T%, tumor percentage; USC, uter
The Journal of Molecular Diagnostics - jmd.amjpathol.orgbe identiﬁed in both the normal and tumor DNA for all
samples in which both were analyzed. All germline variants
were covered by at least 100 reads, and 76% of the variants
had a coverage of >1000 reads.
Deletions and Duplications
To detect exon deletions and duplications in BRCA1, CNV-
MLPA was performed for the eight samples in the training
cohort in which no variant was initially detected by the
pipeline [either using tumor DNA (n Z 4), normal DNA
(nZ 2), or both (nZ 2)]. This resulted in the detection of two
germline deletions of exon 22 (R15 and R40), one germline
deletion of exons 8 and 9 (R50), and two 62-bp deletions in
exon 24 [c.5503_5564del62 and p.Arg1835Thrfs*24 (R26
and R41, respectively)].
Visual inspection of the sequencing reads in Integrative
Genomics Viewer for the remaining three samples revealed an
11-bp deletion (BRCA1; c.3481_3491delGAAGATACTAG)
and a 7-bp deletion (BRCA2; c.9295_9301delAATTTAC) in
samples R32 and R36, respectively. Both deletions were sit-
uated at the end of a PCR amplicon, with only a few base pairs
left on the short side, resulting in misalignment of the reads.
Adjustment of the alignment settings improved the alignment
of the reads, resulting in automatic identiﬁcation of both de-
letions (Supplemental Figure S2).
In sample R24, a known BRCA2 variant could not be
identiﬁed. The patient carried a germline duplication
(c.4284dupT) in a homopolymer stretch of six thymidines.
The duplication could not be identiﬁed because of
sequencing artifacts present at homopolymer regions
(Supplemental Figure S3).
Loss of Heterozygosity
LOH of the wild-type allele was observed in 37 cases
(Table 1), whereas three cases did not show LOH. In the
remaining six cases, the presence of LOH could not be
determined with certainty because of a lack of informative
SNPs and/or failure of sequencing of tumor DNA. Of the 16
HGSCs in which LOH could be determined, all but one
showed LOH [15/16 (94%)].Prospective COBRA Cohort
In total, 66 women were recruited to participate in the
prospective phase of the study (Figure 1B). Four cases (6%)ide variants identiﬁed in the succeeded primer pool.
automatically classiﬁed as delACT, but was later manually curated.
tion; EEC, endometrioid endometrial carcinoma; EOC, endometrioid ovarian
r; ID, identiﬁcation; ILC, invasive lobular carcinoma; LGSC, low-grade serous
not applicable; NST, invasive carcinoma of no special type; OCS, ovarian
ine serous carcinoma; VAF, variant allele frequency.
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Table 2 COBRA Cohort Characteristics
Characteristics Total cohort
No BRCA1/2
defect
BRCA1/2
variant
BRCA1 promoter
hypermethylation P value
Total, n (%) 62 (100) 43 (100) 11 (100) 8 (100)
Age in years, mean (range) 64 (47e89) 66 (47e89) 62 (50e69) 62 (56e71) 0.3
Tumor type
HGSC, n (%) 54 (87) 35 (81) 11 (100) 8 (100) 0.093*
Non-HGSC, n (%)y 8 (13) 8 (19) 0 (0) 0 (0)
*The prevalence of HGSC and non-HGSC was compared between women with and without BRCA1/2 defects.
yThe non-HGSC consisted of two low-grade serous carcinomas, two endometrioid ovarian carcinomas, three ovarian clear cell carcinomas, and one ovarian
carcinosarcoma.
COBRA, clinical implementation of BRCA1/2 screening on ovarian tumor tissue; HGSC, high-grade ovarian, fallopian tube, and primary peritoneal carcinoma.
de Jonge et alwere excluded from the ﬁnal analysis for the following
reasons: insufﬁcient tumor tissue available (n Z 1), quality
control of tumor failed (n Z 1), or no ovarian malignancy
after histologic revision (nZ 2, one metastatic endometrial
cancer and one ovarian serous borderline tumor). The
characteristics of the COBRA cohort are summarized in
Table 2. Fifty-four patients (87%) were diagnosed with
HGSC, and eight patients (13%) were diagnosed with other
histologic subtypes of EOC.
Of the 62 cases included in the ﬁnal analysis, matched
normal FFPE-derived DNA was analyzed for 37 (60%), of
which four failed quality control (Supplemental Table S1).
Variant analysis was performed on FFPE cytology ma-
terial for three samples, two obtained from cytocentrifuged
effusions [pleural ﬂuid (P10) and ascites (P60)] and one
obtained from a lymph node puncture (P64). All produced
data of sufﬁcient quality.
Variant Analysis
In total, 11 class 3, 4, or 5 BRCA1/2 variants were identiﬁed
in the tumors of 62 EOC patients (Table 3). The 10 detected
variants by NGS comprised seven BRCA1 variants, including
three VUSs and three BRCA2 variants, including one VUS.
One genomic deletion of BRCA1 exon 22 was detected by
CNV-MLPA. For six of the mutated cases in which a variant
was detected by NGS, matching normal FFPE-derived DNA
was analyzed, ﬁve of which produced good-quality data. In
one case (P30), the variant was also detected in normal FFPE
material, suggesting a germline origin. The variants in P11,
P14, P52, and P39 were likely somatic, given their absence in
the matched normal DNA samples.
Results were compared with leukocyte germline DNA,
with ﬁndings summarized in Table 3. In the leukocyte
DNA, four germline BRCA1 variants and two germline
BRCA2 variants were detected, all of which were also
detected in tumor DNA, resulting in a 100% concordance in
the detection of germline variants between the tumor DNA
and leukocyte DNA. The remaining four BRCA1 variants
(including two VUSs) and one BRCA2 variant were somatic
variants because they were not detected in the germline
DNA. No germline variants were detected in the remaining
51 samples without a BRCA1/2 variant in tumor DNA.606BRCA1 Promoter Hypermethylation
With possible future clinical relevance in mind, BRCA1
promoter hypermethylation was also analyzed in the tumors.
BRCA1 promoter hypermethylation was found in 8 of 57
cases (14%) that had sufﬁcient tumor DNA available for
methylation-speciﬁc MLPA. None of these cases had a
concurrent pathogenic BRCA1/2 variant.
All 19 BRCA1/2 defects (germline variants, somatic
variants, and hypermethylated cases) were detected in pa-
tients with HGSC. There was no signiﬁcant difference in
age distribution between women with a BRCA1/2 variant,
with BRCA1 promoter hypermethylation, or lacking a
BRCA1/2 defect (P Z 0.3) (Table 2). In cases with a
BRCA1/2 defect, LOH of the wild-type allele could be
determined for 15 of 19 cases (79%). All but one case (93%)
showed LOH, one of which was of the mutated allele (P52).
The tumor in which no LOH was demonstrated and the one
with LOH of the mutant allele both carried a VUS. No
informative SNVs were present on the BRCA1 alleles for the
remaining four cases, precluding the analysis of LOH (three
with BRCA1 promoter hypermethylation and one with
BRCA1 variant). None of the six patients with a germline
BRCA11/2 variant had other malignancies in their personal
history.
Comparing the frequencies of BRCA1/2 defects in HGSC
with The Cancer Genome Atlas Research Network, fewer
germline mutated cases (11% versus 16%), more somatic
mutated cases (9% versus 7%), and more cases with BRCA1
promoter hypermethylation (16% versus 11%) were found
(Supplemental Figure S4).4
Family History
Of the 62 patients included in the ﬁnal analyses, 57 ques-
tionnaires regarding family histories were returned, which
were then studied by clinical geneticists for suggestions that
there was an indication for extra surveillance or manage-
ment options. Regarding patients without germline BRCA1/
2 variants, family history would have resulted in policy
changes for four patients. Three patients had a positive ﬁrst-
degree family history for OC (P12, P52, and P59), and one
patient was suspect for Lynch syndrome (ie, fulﬁlled the
Bethesda criteria; P55). In families with two cases of EOCjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 BRCA1/2 Defects in the COBRA Cohort
ID Histology Gene cDNA change*y
Amino acid
changez T% VAF tumor VAF normal
LOH wild-type
allele
Germline variants
p18 HGSC BRCA1 c.1881C>Gx p.Val627Z 70 0.80 NA Yes
p32 HGSC BRCA1 c.2685_2686delAA p.Pro897fs 85 0.98 NA Yes
p56 HGSC BRCA1 c.5277þ1G>A p.? 80 0.74 NA Yes
p30 HGSC BRCA2 c.4576dupA p.Thr1526fs 80 0.97 0.48 Yes
p62 HGSC BRCA2 c.5117A>Cx p.Asn1706Thr 80 0.54 NA No
CNV-MLPA, germline
p41 HGSC BRCA1 Deletion of exon 22 p.? 30 NAP NAP{ Yes
Somatic variants
p24 HGSC BRCA1 c.3718C>T p.Gln1240* 80 0.76 Not present Yes
p11 HGSC BRCA1 c.3858_3861delTGAG p.Ser1286fs 70 0.56 Not present Yes
p52k** HGSC BRCA1 c.4868C>Gx p.Ala1623Gly 40 0.37 Not present Yesyy
p39 HGSC BRCA1 c.5366C>Tx p.Ala1789Val 95 0.65 Not present Uncertain
p12 HGSC BRCA2 c.209_210delCT p.Ser70fs 70 0.82 QCF Yes
MS-MLPA
p7 HGSC BRCA1 Promoter hypermethylation p.? 80 NAP NA Uncertain
p15 HGSC BRCA1 Promoter hypermethylation p.? 35 NAP NA Yes
p17 HGSC BRCA1 Promoter hypermethylation p.? 80 NAP NA Yes
p23 HGSC BRCA1 Promoter hypermethylation p.? 85 NAP NAP Yes
p25 HGSC BRCA1 Promoter hypermethylation p.? 70 NAP NAP Yes
p36 HGSC BRCA1 Promoter hypermethylation p.? 95 NAP NAP Yes
p58 HGSC BRCA1 Promoter hypermethylation p.? 70 NAP NA Uncertain
p59 HGSC BRCA1 Promoter hypermethylation p.? 70 NAP NA Uncertain
All variants had a coverage well above 100 reads, reaching >1000 reads in 10 of 11 cases (91%).
*Only class 3 (variant of unknown signiﬁcance), class 4 (likely pathogenic), and class 5 (pathogenic) variants are reported.
yReference sequences: NM_007294.3 for BRCA1 and NM_000059.3 for BRCA2.
zNP_009225.1 for BRCA1 and NP_000059.3 for BRCA2.
xVariant of unknown signiﬁcance.
{CNV-MLPA not performed on normal DNA sample.
kDNA concentration too low to perform MS-MLPA.
**Not enough tumor to perform CNV-MLPA.
yyLOH of the mutant allele.
CNV-MLPA, copy number variantemultiplex ligation-dependent probe ampliﬁcation; COBRA, clinical implementation of BRCA1/2 screening on ovarian tumor
tissue; HGSC, high-grade ovarian, fallopian tube, and primary peritoneal cancer; ID, identiﬁcation; LOH, loss of heterozygosity; MS-MLPA, methylation-speciﬁc
MLPA; NA, not analyzed; NAP, not applicable; QCF, quality control failed; T%, tumor percentage; VAF, variant allele frequency.
BRCA1/2 Screening in Tumor Tissuebut no germline variant, the ovarian cancer risk for ﬁrst-
degree female family members is >10%, a level at which
prophylactic surgery should be considered.39 The patient
with a positive ﬁrst-degree family history for colon cancer
<50 years of age had a prior clear cell renal cell carcinoma
but no personal history for colon cancer or endometrial
cancer. Immunohistochemical staining for mismatch repair
proteins did not show abnormalities, making Lynch syn-
drome unlikely. Nevertheless, because the family fulﬁlled
the familial colorectal cancer criteria, advice for 5-yearly
screening of the colon was given.40Discussion
The aim of this study was to evaluate the reliability of
BRCA1/2 variant analysis on FFPE-derived tumor DNA,
using a tumor test consisting of semiconductor sequencingThe Journal of Molecular Diagnostics - jmd.amjpathol.orgwith an amplicon-based BRCA1/2 panel combined with
CNV-MLPA for BRCA1. During optimization of the tumor
test on the training cohort, 45 of 46 variants were detected,
representing a sensitivity of 98% despite enrichment for
challenging variants. During prospective validation in the
COBRA cohort, all six germline BRCA1/2 variants in tumor
DNA were identiﬁed (sensitivity of 100%), together with
the identiﬁcation of an additional ﬁve somatic BRCA1/2
variants and eight cases with BRCA1 promoter hyper-
methylation. These results show that BRCA1/2 variants can
be reliably detected in FFPE-derived DNA. In the COBRA
cohort, referral based on a positive tumor BRCA1/2 variant
screening test result may have reduced the referral rate of
EOC patients to a clinical geneticist by approximately 80%.
The recent approval of the PARP inhibitors niraparib
(US Food and Drug Administration, March 2017, available at
https://www.fda.gov/drugs/informationondrugs/approveddrugs/
ucm548487.htm; European Medicines Agency, November607
Figure 2 Flowchart illustrating the current epithelial ovarian cancer (EOC) BRCA1/2 screening pathway (A) and the proposed EOC BRCA1/2 tumor screening
pathway (B). The integration of tumor tissue analysis for BRCA1/2 variants as part of the ovarian cancer patient pathway is more efﬁcient because it avoids
referral of most patients when only those women carrying a BRCA1/2 mutation or having a suspected family history are being referred for genetic counseling.
Percentages are based on the clinical implementation of BRCA1/2 screening on ovarian tumor tissue cohort.
de Jonge et al2017, available at http://www.ema.europa.eu/ema/index.
jsp?curlZpages/medicines/human/medicines/004249/
human_med_002192.jsp&mid=WC0b01ac058001d124)
and olaparib (USFood andDrugAdministration,August 2017,
available at https://www.fda.gov/drugs/informationondrugs/
approveddrugs/ucm572143.htm) as maintenance treatment
for platinum-sensitive relapsed HGSC regardless of BRCA1/2
mutation status may undermine the necessity for tumor
testing to detect somatic BRCA1/2 variants. However, these
approvals were based on studies showing treatment beneﬁt
(ie, PFS) of PARP inhibitors in a highly selected patient
population (namely, those patients with platinum-sensitive
recurrent HGSC who received at least two lines of platinum-
based chemotherapy).19,20 BRCA1/2 loss is known to confer
sensitivity to platinum-based chemotherapy, and tumors with
similar genomic scars without apparent BRCA1/2 loss also
show increased sensitivity to these agents.13 Therefore,
platinum sensitivity already selects tumors that probably
carry DNA repair defects conferring sensitivity to PARP
inhibitors. When platinum-based chemotherapy cannot be
given or in the event that PARP inhibitors become indicated608for adjuvant treatment in the future, this surrogate marker will
not serve for patient selection and additional biomarkers will
be needed. For the time being, known somatic and germline
BRCA1/2 mutation status helps in the selection of those
patients who will derive the greatest treatment beneﬁt from
PARP inhibitors.19,20,23 For example, in the study by
Ledermann et al,19 compared with placebo, women carrying
BRCA1/2 variants showed longer PFS (11.2 versus 4.3
months) than women without BRCA1/2 variants (7.4 versus
5.5 months).
Although patients with EOC have the highest a priori
probability for germline variants in BRCA1/2, other germ-
line predisposing variants, such as BRIP1, RAD51D, or
RAD51C, have been described.3,9 It is, therefore, important
that patients with a positive family history should still be
referred to the clinical genetic services, independent of the
result of a BRCA1/2 tumor test. For example, in the COBRA
cohort, four patients without a germline BRCA1/2 variant
had a positive family history for either ovarian cancer or
colon cancer, which can be an indication to screen for
variants in additional genes or for relatives to considerjmd.amjpathol.org - The Journal of Molecular Diagnostics
BRCA1/2 Screening in Tumor Tissueprophylactic surgery. A more comprehensive tumor test
incorporating additional genes seems feasible, so this limi-
tation will likely be overcome in the future.
In the COBRA cohort, BRCA1 promoter hypermethylation
was observed in 14% of EOCs. Although hypermethylation
is a well-known and common event in HGSC, its clinical
relevance remains unclear. The presence of LOH in tumors
with BRCA1 promoter hypermethylation, in combination
with the observed homologous recombination deﬁciency via
functional analysis,15 suggests that hypermethylation is an
important driver of tumorigenesis. PARP inhibitor sensitivity
is observed in breast cancer cell lines and xenograft tumors
with epigenetic BRCA1 silencing.41,42 However, it remains
unclear whether this increased sensitivity also applies to
patients with BRCA1 hypermethylated EOC. In a recent
study, BRCA1 hypermethylation was not associated with an
increased PARP inhibitor response,43 whereas in the ARIEL2
trial, a subset of BRCA1-methylated EOC showed a longer
PFS.23 In the absence of clear data on clinical consequences,
testing for BRCA1 promoter hypermethylation in routine
diagnostics may be unnecessary at this time.
It is noteworthy that different populations show different
common BRCA1/2 variants.44 For example, BRCA1
genomic deletions are common founder variants in the
Dutch population,45,46 whereas large deletions in BRCA2
are rare. CNV-MLPA for BRCA2 is, therefore, not routinely
performed. In countries in which BRCA2 exon deletions are
more common (eg, Australia and Italy),46 additional BRCA2
CNV-MLPA might be necessary.
The wide mutation spectrum seen in BRCA1/2 and the
presence of variants for which the clinical signiﬁcance is
unclear make interpretation of results challenging.24 Of the
six germline BRCA1/2 variants identiﬁed in the COBRA
cohort, two were VUSs. Because this category of variants
has unclear pathogenicity, it is important that they are dis-
cussed in a multidisciplinary team that includes an expert
clinical molecular geneticist.47
In the training cohort, we showed the importance of opti-
mizing the bioinformatics process for data analysis to prevent
variants present in the sequencing data from not being
reported automatically. This was also shown by others.48
Because BRCA1/2 screening of ovarian tumor tissue has
proved to be a reliable test both in this study and in previous
studies,25,32 we propose that screening of tumor tissue for
BRCA1/2 variants should be implemented in routine
diagnostics, as illustrated in Figure 2. Using the tumor
screening test to identify women with BRCA1/2 variants
(either germline or somatic in origin) provides an efﬁcient
selection method for referral to clinical genetic services.
This scheme resembles the previously adopted Lynch syn-
drome tumor screening program for colorectal and endo-
metrial cancer.9,49 When a BRCA1/2 variant is identiﬁed in
the tumor screening test, women can be referred for genetic
counseling and may subsequently decide whether they want
to know if the variant has a germline origin. This scheme is
particularly beneﬁcial to those patients (and their relatives)The Journal of Molecular Diagnostics - jmd.amjpathol.orgwithout a BRCA1/2 variant, as tumor screening will prevent
unnecessary distress because of a possible hereditary origin
of the EOC. An additional advantage of tumor screening is
that subsequent germline analysis only requires veriﬁcation
of a speciﬁc variant, avoiding the need (and associated
costs) for whole-gene scanning. On the basis of these con-
siderations, implementation of BRCA1/2 tumor screening in
the care pathway of EOC patients may be an efﬁcient and
patient-friendly approach.
Although BRCA1/2 tumor screening proved to be highly
sensitive, some technical limitations were observed.
Sequencing artifacts present in homopolymer regions pre-
vented the detection of oneBRCA2 variant in the training cohort
(Supplemental Figure S3). Previous studies have already
highlighted the high rates of error in insertion/deletion calling
associated with homopolymer regions.25,29,30,50,51 On the basis
of data extracted from the Leiden Open Variant Database
(http://www.lovd.nl/3.0/home, last accessed October 13,
2017),28 in combination with our institutional data, we esti-
mate that approximately one homopolymer germline BRCA1/2
variant in every 250 patients screened could be missed
(Supplemental Table S2). Use of improved sequencing chem-
istry or sequencing platforms that showbetter performancewith
homopolymer regions will mitigate this problem.51
A technical limitation, which applies to all amplicon-
based sequencing techniques, is the possibility of variants
being located at amplicon ends or primer binding sites.
Because FFPE-derived DNA is highly fragmented, shorter
amplicons are needed, thus increasing the chance of variants
being present in amplicon edges or primer locations.
In this study, we optimized and clinically validated a
BRCA1/2 variant tumor screening test of FFPE material. It
was demonstrated that the test has adequate sensitivity to
detect BRCA1/2 variants. Therefore, a workﬂow in which
BRCA1/2 tumor screening is requested by the treating
physician and is integrated in routine care for all EOC pa-
tients is recommended. This will allow more efﬁcient pa-
tient selection for precision medicine, genetic counseling,
and preventive options. Awareness of family history re-
mains important, and referral to genetic services should be
based on both the detection of variants in the tumor test and
the presence of affected cases in family histories.Acknowledgments
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